Respondents ranked labor shortages and closing healthcare disparities the highest when asked what about most important issues facing U.S. healthcare in 2023.
What issues and challenges in healthcare will loom the largest this year?
That was question we asked in our annual State of the Industry this year. Respondents rated issues on a scale of 1-10 with 10 being the most important. We then weighted the answers with 10 having a value of 10, 9 having a value of 9, and so on.
The results were close but labor shortages ranked the highest in importance (weighted score of 6.73), followed by closing healthcare disparities (6.69) and long covid (6.63).
Adoption of the biosimilars (6.37) and interoperability (6.27) came out at the bottom of the importance ranking.
It is not surprising that labor shortages topped the list. The news has been full of stories about staffing shortages and related labor unrest. The U.S. Bureau of Labor Statistics has projected that there will be 200,000 openings for registered nurses each year over the next eight years. The bureau says employment of nurses is expected to grow by 6% in the 2020s, but that is about the same rate of growth as other occupations. The openings are the result of retirements and people leaving nursing for other professions.
The MHE State of the Survey was conducted in late November and early December 2022. Our colleagues at Medical Economics® helped disseminate the survey. The survey had just over 450 respondents.
In this first part of a two-part podcast episode, Managed Healthcare Executive's Managing Editor Peter Wehrwein kicks off our new podcast series "DC Roundtable," with guests Margaret "Meg" Murray, CEO of the Association of Community Affiliated Plans, and member of MHE's Editorial Advisory Board, and CeCi Connolly, president and CEO of the Alliance of Community Health Plans, for a discussion on healthcare policy issues.
Listen
New approvals this week include a $4.25 million gene therapy, a drug that treats hypertension in a new way, a nonsteroidal drug for Duchenne, and an oral drug for aggressive leukemia. The agency has set an action date for resubmitted Lymphir in rare skin cancer, and Celltrion has launched Zymfentra, a subcutaneous form of infliximab.
Read More